Drug Profile
Mezigdomide - Bristol-Myers Squibb
Alternative Names: A/I CELMoD - Bristol-Myers Squibb; BMS-986348; CC-92480; CELMoD CC-92480; Cereblon E3 Ligase Modulation Drug CC-92480; Cereblon E3 Ubiquitin Ligase Modulating Agent CC-92480; Cereblon Modulator CC-92480; MEZILatest Information Update: 22 Mar 2024
Price :
$50
*
At a glance
- Originator Celgene Corporation
- Developer Bristol-Myers Squibb; Celgene Corporation
- Class Antineoplastics; Fluorobenzenes; Isoindoles; Nitriles; Piperazines; Piperidines; Small molecules
- Mechanism of Action Apoptosis stimulants; CRBN protein modulators; Ubiquitin protein ligase modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Multiple myeloma
Most Recent Events
- 15 Mar 2024 Celgene plans a phase I pharmacokinetics trial (In volunteers, In adults, In the elderly) in USA, March 2024 (NCT06318676)
- 27 Feb 2024 Phase-I/II clinical trials in Multiple myeloma (Combination therapy, Second-line therapy or greater) in Israel, USA (unspecified route) (NCT061638980 (700369505)
- 11 Dec 2023 Efficacy, pharmacodynamic and adverse events data from a phase-I/II trial in Multiple myeloma presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2023)